03.10.2019 | Insight

3 reasons for renewed hope in the treatment landscape of acute myeloid leukaemia

By Mary Kangley

3 reasons for renewed hope in the treatment landscape of acute myeloid leukaemia

The treatment landscape of acute myeloid leukaemia (AML), which historically has been undertreated and considered a medical emergency with poor prognosis, is becoming full of hope for newly diagnosed patients. With recent clinical trials and drug approvals, a once bleak landscape is being transformed.

Healthcare professionals (HCPs) have been discussing these changes on social media. In the UK, for example, 10% of posts by HCPs over the past year mentioned specific new treatments for the disease. CREATION.co’s human sentiment analysis of these posts illuminated a positive anticipation for these products.

1. Data for patients over 60

Congress meetings are always a key time for HCPs to respond to trial results of new and existing products. In December 2018, UK HCPs shared data that had been presented during the American Society of Hematology, #ASH18, showing encouraging results. One example was a “promising” trial of venetoclax (AbbVie’s Venclyxto) and idasanutlin (Roche) in AML patients over the age of 60.

While these results were emerging, HCPs in the UK shared a post from David Steensma, a US haematologist-oncologist who highlighted the cost barrier for patients who could only afford novel treatments via clinical trials. The tweet sparked a discussion around cost benefit. Navneet Majhail, another US doctor, suggested bone marrow transplantation will be more cost-effective, while Steensma said plainly that whilst there had been many recent approvals, these will not all necessarily aid patients.

Amidst these cautions, more trials were completed and data shared. HCPs often respond on social media to not only new advances in treatment but also disappointments in data. Their understanding of the landscape is shaped broadly by the trial statistics, commentary from their peers and sometimes provocative discussions that unite clinicians from all backgrounds and therapy areas.

2. Maintenance treatment data

One area seeing advancement is maintenance treatment for AML patients post intense chemotherapy or bone marrow transplant. In April, results of a trial investigating azacitidine maintenance were released, headlining an improved disease-free survival (DFS). However, HCPs online quickly noted the DFS survival did not relate to overall survival (OS); they showed their concerns that these results may not affect treatment behaviour.

Updated news in September came of Celgene’s Phase III QUAZAR trial meeting its primary and secondary endpoints for oral-azacitidine post-chemotherapy (OS and relapse-free survival, RFS). HCPs in the UK shared this news but without additional comment.

Following this, UK HCPs were keen to share the opening of the AMADEUS trial for post-transplant oral azacitidine, the first of its kind. The online behaviours of HCPs show their consistent desire for research into new products and evidence that they will be safe and effective for their patients, never fully satiated with the latest release.

3. A new standard of care

Whilst many continually seek further data, one oncologist in London, Sarah Halford, suggested the results of the ADMIRAL trial may call for a new standard of care in Astellas’ Xospata. This bold question exemplifies the strong opinions HCPs are willing to air on social media, asking for and providing a means for group analysis and consideration that may not be feasible offline.

Even with new products being added to the AML treatment landscape, there was still bad news for the therapy area. In July, the FDA declined Daiichi Sankyo’s quizartinib for the treatment of FLT3-mutated AML. HCPs were disappointed that another potential new treatment option for patients failed to reach the mark.


Most recently, an EMA positive recommendation of Astellas’ gilteritinib (Xospata) as a monotherapy gave UK HCPs a renewed hope for their patients in the NHS. The online response showed HCPs were cautious about the possibility of novel treatments, aware of the knowledge that an approval does not immediately equate to a newly accessible drug for patients. Mike Dennis, a hematologist-oncologist from Manchester, commented that the approval may mean UK NHS patients could receive the treatment that previously was not an option.

A renewed hope in AML

2019 has seen a wave of change in the AML treatment landscape, with both successes and failures. HCPs tracked this evolution on social media, celebrating and cautiously anticipating new data and possible options, such as Astellas’ Xospata, and sharing disappointment when products failed to meet hopes, namely Daiichi Sankyo’s quizartinib. As the market changes, HCPs will inevitably continue to vocalise their reactions on social media. The tracking of these reactions allow for the isolated and unprompted voice of HCPs to come to light.

The developments in maintenance therapy were particularly well tracked by UK HCPs. As these advancements continue, they will present a key opportunity for pharmaceutical companies to engage with their HCP customers.

Monthly, CREATION Pinpoint tracks the online HCP response to various pharmaceutical matters including drug approvals and pharma engagement. For bespoke HCP insights, get in touch.

The header image is of ‘human cells with acute myelocytic leukemia (AML) in the pericardial fluid, shown with an esterase stain at 400x’ and was released by the National Cancer Institute.

View all articles >

Meet the Author

Mary Kangley

Mary is passionate about telling stories with data from online healthcare conversations. Her work is guided by a background in human and cyber-psychology providing a curiosity to understand what HCPs think.

As a keen music fan, Mary’s greatest pride is her Spotify playlists that are continually growing as she makes new discoveries.

Suggested next

02.07.2022 | Article

Product Launch Tracker: HCPs celebrate 5th agnostic approval in Cancer alongside other approvals

with notable excitement being found for the FDA’s approval of Novartis’ 5th agnostic...

By Paul Cranston and Tomi Shobande

A new gynaecological cancer hashtag emerges at ASCO2020

15.07.2020 | Article

A new gynaecological cancer hashtag emerges at ASCO2020

A new gynaecological cancer hashtag emerges at ASCO2020

By Jamie Doggett

View all articles >